Amedeo Smart

Free Medical Literature Service

 

Amedeo

Irritable Bowel Syndrome
  Free Subscription

Articles published in
Aliment Pharmacol Ther
    April 2024
  1. ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
    Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
    Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
    >> Share

    February 2024
  2. STALLER K, Ludvigsson JF
    Letter: Irritable bowel syndrome and antibiotics-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:422.
    >> Share

  3. LONGSTRETH GF
    Letter: Irritable bowel syndrome and antibiotics.
    Aliment Pharmacol Ther. 2024;59:421.
    >> Share

  4. BLACK CJ, Gracie DJ
    Editorial: A Mediterranean diet for IBS-Is healthy and inclusive eating the way forward?
    Aliment Pharmacol Ther. 2024;59:571-572.
    >> Share

    January 2024
  5. SHIN A
    Editorial: Antibiotics as a risk factor for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2024;59:130-131.
    >> Share

  6. CHANG HC, Gau SY
    Letter: antibiotics prescription and new-onset irritable bowel syndrome.
    Aliment Pharmacol Ther. 2024;59:299.
    >> Share

    December 2023
  7. STALLER K, Ludvigsson JF
    Letter: Antibiotics prescription and new-onset irritable bowel syndrome-Authors' reply.
    Aliment Pharmacol Ther. 2023 Dec 8. doi: 10.1111/apt.17827.
    >> Share

    November 2023
  8. STAUDACHER HM, Mahoney S, Canale K, Opie RS, et al
    Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Nov 15. doi: 10.1111/apt.17791.
    >> Share

  9. DEVENNEY J, Hasan SS, Morris J, Whorwell PJ, et al
    Clinical trial: predictive factors for response to gut-directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis.
    Aliment Pharmacol Ther. 2023 Nov 5. doi: 10.1111/apt.17790.
    >> Share

  10. EL-SALHY M, Gilja OH, Hatlebakk JG
    Letter: A step forward towards a standard FMT protocol for IBS.
    Aliment Pharmacol Ther. 2023;58:1115-1116.
    >> Share

  11. LESMANA E, Grover M
    Editorial: Faecal microbiota transplantation in IBS-Moving closer or away from success?
    Aliment Pharmacol Ther. 2023;58:950-951.
    >> Share

  12. SU Q, Yau YK, Ng SC
    Editorial: Faecal microbiota transplantation in IBS-Moving closer or away from success? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:952-953.
    >> Share

    October 2023
  13. DAJTI E, Frazzoni L, Iascone V, Secco M, et al
    Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
    >> Share

    September 2023
  14. STALLER K, Olen O, Soderling J, Roelstraete B, et al
    Antibiotic use as a risk factor for irritable bowel syndrome: Results from a nationwide, case-control study.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17736.
    >> Share

  15. YAU YK, Su Q, Xu Z, Tang W, et al
    Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2023 Sep 5. doi: 10.1111/apt.17703.
    >> Share

  16. MELTON SL, Halmos EP
    Editorial: One step closer to personalised nutrition therapy for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:554-555.
    >> Share

    August 2023
  17. CHUAH KH, Black CJ, Tee V, Lim SZ, et al
    Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply.
    Aliment Pharmacol Ther. 2023;58:476-477.
    >> Share

  18. GHOSHAL UC
    Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never!
    Aliment Pharmacol Ther. 2023;58:474-475.
    >> Share

    July 2023
  19. LUO Y, Jodorkovsky D, Singh P, Keefer LA, et al
    Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:137-138.
    >> Share

  20. DAI C, Huang YH, Jiang M
    Letter: Post-COVID-19 functional dyspepsia and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:126-127.
    >> Share

  21. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2023;58:139-140.
    >> Share

  22. MARASCO G, Maida M, Cremon C, Barbaro MR, et al
    Letter: Post-COVID-19 functional dyspepsia and irritable bowel syndrome-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:128-129.
    >> Share

    June 2023
  23. SO D, Yao CK, Gill PA, Thwaites PA, et al
    Detection of changes in regional colonic fermentation in response to supplementing a low FODMAP diet with dietary fibres by hydrogen concentrations, but not by luminal pH.
    Aliment Pharmacol Ther. 2023 Jun 30. doi: 10.1111/apt.17629.
    >> Share

  24. WILSON B, Kanno T, Slater R, Rossi M, et al
    Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Jun 14. doi: 10.1111/apt.17609.
    >> Share

  25. GUNN D, Ford A, Farrin A, Spiller R, et al
    Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1337-1338.
    >> Share

  26. SHAH ED
    Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms.
    Aliment Pharmacol Ther. 2023;57:1335-1336.
    >> Share

  27. CHUAH KH, Black CJ, Tee V, Lim SZ, et al
    A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care.
    Aliment Pharmacol Ther. 2023 Jun 1. doi: 10.1111/apt.17567.
    >> Share

    May 2023
  28. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1190-1191.
    >> Share

  29. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1176-1177.
    >> Share

  30. SHARMA A, Rao S
    Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options!
    Aliment Pharmacol Ther. 2023;57:1174-1175.
    >> Share

  31. CHUAH KH, Mahadeva S
    Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients?
    Aliment Pharmacol Ther. 2023;57:1188-1189.
    >> Share

    April 2023
  32. MARASCO G, Maida M, Cremon C, Barbaro MR, et al
    Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17513.
    >> Share

    March 2023
  33. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Mar 13. doi: 10.1111/apt.17465.
    >> Share

  34. GUNN D, Topan R, Barnard L, Fried R, et al
    Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.
    Aliment Pharmacol Ther. 2023 Mar 3. doi: 10.1111/apt.17426.
    >> Share

  35. THWAITES PA, Burgell RE
    Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here?
    Aliment Pharmacol Ther. 2023;57:723-724.
    >> Share

  36. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:725-726.
    >> Share

    February 2023
  37. MANTEGAZZA G, Gargari G, Guglielmetti S
    Editorial: bacterial gut symbionts as live biotherapeutic agents in irritable bowel syndrome-a rosy future despite potential long-term safety concerns.
    Aliment Pharmacol Ther. 2023;57:345-346.
    >> Share

  38. QUIGLEY EMM, Stevenson A, Jeffery I, Masters J, et al
    Editorial: bacterial gut symbionts as live biotherapeutic agents in IBS-a rosy future despite potential long-term safety concerns. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:347-348.
    >> Share

  39. WANG L, Alexander JA
    Letter: diet-responsive or just diet-adherent in EoE. Where is the dietitian? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:445.
    >> Share

    January 2023
  40. MAALOUF E, Grover M
    Editorial: repurposed linaclotide and the quest for abdominal pain management in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;57:261-262.
    >> Share

    December 2022
  41. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Dec 21. doi: 10.1111/apt.17356.
    >> Share

  42. FITZPATRICK JA, Halmos EP
    Editorial: gluten-free but not pain-free in IBS.
    Aliment Pharmacol Ther. 2022;56.
    >> Share

  43. ALGERA JP, Magnusson MK, Ohman L, Storsrud S, et al
    Editorial: gluten-free but not pain-free in IBS-authors' reply.
    Aliment Pharmacol Ther. 2022;56.
    >> Share

    November 2022
  44. QUIGLEY EMM, Markinson L, Stevenson A, Treasure FP, et al
    Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Nov 11. doi: 10.1111/apt.17310.
    >> Share

  45. LEMBO A, Kuo B, Boinpally R, Li E, et al
    Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2022 Nov 2. doi: 10.1111/apt.17274.
    >> Share

  46. QUIGLEY EMM
    Editorial: 5-aminosalicylic acid fails to impact on irritable bowel syndrome-wrong population, intervention, target or hypothesis?
    Aliment Pharmacol Ther. 2022;56:1497-1498.
    >> Share

    October 2022
  47. GU Y, Xiang Y
    Letter: efficacy of peppermint oil in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:1215-1216.
    >> Share

  48. INGROSSO MR, Ianiro G, Nee J, Lembo AJ, et al
    Letter: efficacy of peppermint oil in irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1217-1218.
    >> Share

  49. SHIN A
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1300-1301.
    >> Share

  50. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1302-1303.
    >> Share

    September 2022
  51. ALGERA JP, Magnusson MK, Ohman L, Storsrud S, et al
    Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Sep 29. doi: 10.1111/apt.17239.
    >> Share

  52. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:894-895.
    >> Share

  53. SHAH ED, Wechsler EV
    Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:892-893.
    >> Share

    August 2022
  54. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
    >> Share

  55. INGROSSO MR, Ianiro G, Nee J, Lembo AJ, et al
    Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Aug 9. doi: 10.1111/apt.17179.
    >> Share

  56. CASTRO TEJERA V, Ohman L, Aabakken L, Fellstrom B, et al
    Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-Effects on gastrointestinal symptoms and rectal biomarkers of immune activity.
    Aliment Pharmacol Ther. 2022 Aug 8. doi: 10.1111/apt.17182.
    >> Share

    July 2022
  57. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Impact of Rome IV Irritable Bowel Syndrome on Work and Activities of Daily Living.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17132.
    >> Share

  58. LOVDAHL J, Tornblom H, Ringstrom G, Palsson OS, et al
    Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2022;56:160-161.
    >> Share

  59. MIKOCKA-WALUS A, Lores T
    Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:158-159.
    >> Share

  60. BIESIEKIERSKI JR, Wu J, Van Oudenhove L
    Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:368-369.
    >> Share

  61. HALMOS EP, Gibson PR
    Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs.
    Aliment Pharmacol Ther. 2022;56:366-367.
    >> Share

  62. BIESIEKIERSKI JR, Manning LP, Murray HB, Vlaeyen JWS, et al
    Review article: Exclude or expose? The paradox of conceptually opposite treatments for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Jul 1. doi: 10.1111/apt.17111.
    >> Share

    June 2022
  63. COFFIN PB, Duboc H
    Diagnostic and therapeutic approach to persistent abdominal pain beyond irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Jun 2. doi: 10.1111/apt.17064.
    >> Share

  64. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1590-1591.
    >> Share

  65. BERINSTEIN JA, Fendrick AM
    Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition.
    Aliment Pharmacol Ther. 2022;55:1588-1589.
    >> Share

    May 2022
  66. LOVDAHL J, Tornblom H, Ringstrom G, Palsson OS, et al
    Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16934.
    >> Share

  67. QUIGLEY EMM
    Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?
    Aliment Pharmacol Ther. 2022;55:1218-1219.
    >> Share

  68. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
    Aliment Pharmacol Ther. 2022 May 1. doi: 10.1111/apt.16939.
    >> Share

    April 2022
  69. FOX M
    Editorial: meal-induced symptoms in irritable bowel syndrome-"all in the mind"?
    Aliment Pharmacol Ther. 2022;55:880-881.
    >> Share

    February 2022
  70. WU J, Masuy I, Biesiekierski JR, Fitzke HE, et al
    Gut-brain axis dysfunction underlies FODMAP-induced symptom generation in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16812.
    >> Share

  71. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16816.
    >> Share

    December 2021
  72. LIU JJ, Brenner DM
    Review article: current and future treatment approaches for IBS with constipation.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S53-S62.
    >> Share

  73. SHIHA MG, Aziz I
    Review article: Physical and psychological comorbidities associated with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S12-S23.
    >> Share

  74. YADAV YS, Eslick GD, Talley NJ
    Review article: irritable bowel syndrome: natural history, bowel habit stability and overlap with other gastrointestinal disorders.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S24-S32.
    >> Share

  75. NEE J, Lembo A
    Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M).
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S63-S74.
    >> Share

  76. BLACK CJ
    Review article: Diagnosis and investigation of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S33-S43.
    >> Share

  77. RUDDY J
    Review article: the patients' experience with irritable bowel syndrome and their search for education and support.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S44-S52.
    >> Share

  78. SPERBER AD
    Review article: epidemiology of IBS and other bowel disorders of gut-brain interaction (DGBI).
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S1-S11.
    >> Share

  79. PAINE P
    Review article: current and future treatment approaches for pain in IBS.
    Aliment Pharmacol Ther. 2021;54 Suppl 1:S75-S88.
    >> Share

    November 2021
  80. GROVER M, Berumen A, Peters S, Wei T, et al
    Editorial: understanding IBS pathophysiology through "converging channels" of research-authors' reply.
    Aliment Pharmacol Ther. 2021;54:1215-1216.
    >> Share

  81. ELWING JE, Sayuk GS
    Editorial: understanding IBS pathophysiology through "converging channels" of research.
    Aliment Pharmacol Ther. 2021;54:1213-1214.
    >> Share

    October 2021
  82. DELLSCHAFT N, Hoad C, Marciani L, Gowland P, et al
    Small bowel water content assessed by MRI in health and disease: a collation of single-centre studies.
    Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16673.
    >> Share

  83. MCNAUGHTON DT, Andreasson A, Ljotsson B, Beath AP, et al
    Limited evidence of moderation of the association between gastrointestinal symptoms and prospective healthcare utilisation by quality of life.
    Aliment Pharmacol Ther. 2021 Oct 19. doi: 10.1111/apt.16651.
    >> Share

  84. ZAND IRANI M, Jones MP, Halland M, Herrick L, et al
    Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population-based study.
    Aliment Pharmacol Ther. 2021 Oct 9. doi: 10.1111/apt.16630.
    >> Share

    September 2021
  85. GILLAN C
    Review article: the effectiveness of group and self-help hypnotherapy for irritable bowel syndrome and the implications for improving patients' choice and access to treatment.
    Aliment Pharmacol Ther. 2021 Sep 30. doi: 10.1111/apt.16623.
    >> Share

  86. GROVER M, Berumen A, Peters S, Wei T, et al
    Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression.
    Aliment Pharmacol Ther. 2021 Sep 2. doi: 10.1111/apt.16591.
    >> Share

    August 2021
  87. AKBANI U, Vasant DH
    Editorial: important insights into prescribing practices and training needs of gastroenterologists regarding use of central neuromodulators in IBS.
    Aliment Pharmacol Ther. 2021;54:339-340.
    >> Share

    July 2021
  88. KOLOSKI NA, Jones M, Walker MM, Keely S, et al
    Sleep disturbances in the irritable bowel syndrome and functional dyspepsia are independent of psychological distress: a population-based study of 1322 Australians.
    Aliment Pharmacol Ther. 2021 Jul 11. doi: 10.1111/apt.16500.
    >> Share

  89. NELSON AD, Black CJ, Houghton LA, Lugo-Fagundo NS, et al
    Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating-a step in the right direction for targeted treatment? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:198-199.
    >> Share

  90. TALLEY NJ, Walker MM, Agreus L, Andreasson A, et al
    Editorial: tobacco use in functional dyspepsia-another smoking gun? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:79.
    >> Share

  91. WOO MMK, Andrews CN
    Editorial: tobacco use in functional dyspepsia-another smoking gun?
    Aliment Pharmacol Ther. 2021;54:78.
    >> Share

  92. VASANT DH
    Editorial: recognising the efficacy of licensed drug therapies for IBS on bloating-a step in the right direction for targeted treatment?
    Aliment Pharmacol Ther. 2021;54:196-197.
    >> Share

    June 2021
  93. NULSEN B, LeBrett W, Drossman DA, Chang L, et al
    A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16467.
    >> Share

  94. NELSON AD, Black CJ, Houghton LA, Lugo-Fagundo NS, et al
    Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16437.
    >> Share

    May 2021
  95. TALLEY NJ, Powell N, Walker MM, Jones MP, et al
    Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population-based studies.
    Aliment Pharmacol Ther. 2021 May 13. doi: 10.1111/apt.16372.
    >> Share

  96. SIMONS M, Taft TH
    Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management.
    Aliment Pharmacol Ther. 2021;53:1151-1152.
    >> Share

  97. BLACK CJ, Ford AC
    Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management-authors' reply.
    Aliment Pharmacol Ther. 2021;53:1153-1154.
    >> Share

    March 2021
  98. BLACK CJ, Yiannakou Y, Guthrie E, West R, et al
    Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value.
    Aliment Pharmacol Ther. 2021 Mar 11. doi: 10.1111/apt.16322.
    >> Share

  99. HALMOS EP
    Editorial: defining a microbial signature to predict non-response to a FODMAP diet-a step closer or is it?
    Aliment Pharmacol Ther. 2021;53:646-647.
    >> Share

  100. CHUMPITAZI BP, Shulman RJ
    Editorial: defining a microbial signature to predict non-response to a low FODMAP diet-a step closer or is it? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:648-649.
    >> Share

    December 2020
  101. CHUMPITAZI BP, Hoffman KL, Smith DP, McMeans AR, et al
    Fructan-sensitive children with irritable bowel syndrome have distinct gut microbiome signatures.
    Aliment Pharmacol Ther. 2020 Dec 13. doi: 10.1111/apt.16204.
    >> Share

  102. PERTTU L, Jonna J, Anna H, Eero M, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-which improvements are required? Authors' reply.
    Aliment Pharmacol Ther. 2020;52.
    >> Share

  103. EL-SALHY M, Hausken T, Gunnar Hatlebakk J
    Letter: faecal microbiota transplantation for irritable bowel syndrome-which improvements are required?
    Aliment Pharmacol Ther. 2020;52.
    >> Share

    October 2020
  104. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Letter: placebo run-in for IBS clinical trials - is it useful? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1239-1240.
    >> Share

  105. BOSMAN MHMA, Keszthelyi D
    Letter: placebo run-in for IBS clinical trials-is it useful?
    Aliment Pharmacol Ther. 2020;52:1237-1238.
    >> Share

    September 2020
  106. IANIRO G, Porcari S, Ford AC, Gasbarrini A, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement.
    Aliment Pharmacol Ther. 2020;52:923-924.
    >> Share

  107. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:925-926.
    >> Share

    August 2020
  108. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:557-558.
    >> Share

  109. XU E, Vilella RC, Segal JP, Mullish BH, et al
    Letter: faecal microbiota transplantation for IBS.
    Aliment Pharmacol Ther. 2020;52:556-557.
    >> Share

  110. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Editorial: minesapride for irritable bowel syndrome with constipation-authors' reply.
    Aliment Pharmacol Ther. 2020;52:715-716.
    >> Share

  111. BLACK CJ, Barberio B, Ford AC
    Editorial: minesapride for irritable bowel syndrome with constipation.
    Aliment Pharmacol Ther. 2020;52:713-714.
    >> Share

    June 2020
  112. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
    Aliment Pharmacol Ther. 2020 Jun 25. doi: 10.1111/apt.15907.
    >> Share

  113. GIBSON PR, Halmos EP, Muir JG
    Review article: FODMAPS, prebiotics and gut health. The FODMAP hypothesis revisited.
    Aliment Pharmacol Ther. 2020 Jun 20. doi: 10.1111/apt.15818.
    >> Share

  114. OSTOJIC SM
    Letter: balancing gut hydrogen as a proxy for bacteriotherapy benefits in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020;51:1451-1452.
    >> Share

    May 2020
  115. RAO SSC, Xiang X, Yan Y, Rattanakovit K, et al
    Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
    Aliment Pharmacol Ther. 2020 May 13. doi: 10.1111/apt.15772.
    >> Share

  116. BASILISCO G, Barbara G, Bellini M, Cataudella G, et al
    Editorial: symptom improvement does not equal satisfaction with treatment for constipation-authors' reply.
    Aliment Pharmacol Ther. 2020;51:910-911.
    >> Share

  117. BALLOU S, Lembo A
    Editorial: symptom improvement does not equal satisfaction with treatment for constipation.
    Aliment Pharmacol Ther. 2020;51:909-910.
    >> Share

    April 2020
  118. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15740.
    >> Share

    February 2020
  119. BASILISCO G
    Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients.
    Aliment Pharmacol Ther. 2020 Feb 12. doi: 10.1111/apt.15657.
    >> Share

    January 2020
  120. REJ A, Buckle RL, Shaw CC, Trott N, et al
    Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020;51:184-185.
    >> Share

  121. TUCK C, Vanner S, Camilleri M, Jing Wang X, et al
    Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:185-186.
    >> Share

  122. FORD AC
    Commentary: estimating the prevalence of IBS globally-past, present and future.
    Aliment Pharmacol Ther. 2020;51:198-199.
    >> Share

  123. VAKIL N
    Commentary: tegaserod and IBS, two decades on.
    Aliment Pharmacol Ther. 2020;51:200-201.
    >> Share

    May 2019
  124. FORD AC, Harris LA, Lacy BE, Quigley EMM, et al
    Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1254-1255.
    >> Share

  125. SUN P, Zhang W, Miao Y, Chen Z, et al
    Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS.
    Aliment Pharmacol Ther. 2019;49:1253-1254.
    >> Share

    April 2019
  126. MITCHELL H, Porter J, Gibson PR, Barrett J, et al
    Letters: low FODMAP diet-directions for future research and the low FODMAP diet is not the only diet for IBS-authors' reply.
    Aliment Pharmacol Ther. 2019;49:1109-1110.
    >> Share

  127. O'BRIEN L, Brown S, Gearry RB, Day AS, et al
    Letter: low FODMAP diet-directions for future research.
    Aliment Pharmacol Ther. 2019;49:1107-1108.
    >> Share

  128. REJ A, Trott N, Sanders DS, Aziz I, et al
    Letter: the low FODMAP diet is not the only diet for IBS.
    Aliment Pharmacol Ther. 2019;49:1108-1109.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016